The research team in the Netherlands asks a very important question about the implications of the European Comission's proposition for shortening administrative procedures and investing more money in rare disease research, in addition to promoting increased and faster sharing of research data. This final proposition will likely not sit well with the pharmaceutical industry.
To read their post, follow this link: https://www.socialpharmaceuticalinnovation.org/post/rare-disease-research-in-europe-will-academia-pick-up-the-gauntlet
Please share your opinions on this matter below.